CXCL9 (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "CXCL9" in English language version.

refsWebsite

Global rank English rank

32nih.gov

4^th place

19doi.org

2^nd place

3semanticscholar.org

11^th place

8^th place

2ensembl.org

1,626^th place

1,007^th place

1zenodo.org

621^st place

380^th place

1worldcat.org

5^th place

1harvard.edu

18^th place

17^th place

1maastrichtuniversity.nl

low place

doi.org

Tokunaga R, Zhang W, Naseem M, Puccini A, Berger MD, Soni S, et al. (February 2018). "CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy". Cancer Treatment Reviews. 63: 40–47. doi:10.1016/j.ctrv.2017.11.007. PMC 5801162. PMID 29207310.
Lee HH, Farber JM (1996). "Localization of the gene for the human MIG cytokine on chromosome 4q21 adjacent to INP10 reveals a chemokine "mini-cluster"". Cytogenetics and Cell Genetics. 74 (4): 255–258. doi:10.1159/000134428. PMID 8976378.
O'Donovan N, Galvin M, Morgan JG (1999). "Physical mapping of the CXC chemokine locus on human chromosome 4". Cytogenetics and Cell Genetics. 84 (1–2): 39–42. doi:10.1159/000015209. PMID 10343098. S2CID 8087808.
Tensen CP, Flier J, Van Der Raaij-Helmer EM, Sampat-Sardjoepersad S, Van Der Schors RC, Leurs R, et al. (May 1999). "Human IP-9: A keratinocyte-derived high affinity CXC-chemokine ligand for the IP-10/Mig receptor (CXCR3)". The Journal of Investigative Dermatology. 112 (5): 716–722. doi:10.1046/j.1523-1747.1999.00581.x. PMID 10233762.
Valdés N, Espinoza D, Pareja-Barrueto C, Olate N, Barraza-Rojas F, Benavides-Larenas A, et al. (2024). "Expression and regulation of the CXCL9-11 chemokines and CXCR3 receptor in Atlantic salmon (Salmo salar)". Frontiers in Immunology. 15: 1455457. doi:10.3389/fimmu.2024.1455457. PMC 11410577. PMID 39301034.
Schoenborn JR, Wilson CB (2007). Regulation of interferon-gamma during innate and adaptive immune responses. Advances in Immunology. Vol. 96. Elsevier. pp. 41–101. doi:10.1016/s0065-2776(07)96002-2. ISBN 978-0-12-373709-0. PMID 17981204.
Fernandez-Poma SM, Salas-Benito D, Lozano T, Casares N, Riezu-Boj JI, Mancheño U, et al. (July 2017). "+ T cells Expressing PD-1 Improves the Efficacy of Adoptive T-cell Therapy". Cancer Research. 77 (13): 3672–3684. doi:10.1158/0008-5472.CAN-17-0236. PMID 28522749.
Gorbachev AV, Kobayashi H, Kudo D, Tannenbaum CS, Finke JH, Shu S, et al. (2007-02-15). "CXC Chemokine Ligand 9/Monokine Induced by IFN- Production by Tumor Cells Is Critical for T Cell-Mediated Suppression of Cutaneous Tumors". Journal of Immunology. 178 (4). Baltimore, Md.: 2278–2286. doi:10.4049/jimmunol.178.4.2278. ISSN 0022-1767. PMID 17277133.
Zohar Y, Wildbaum G, Novak R, Salzman AL, Thelen M, Alon R, et al. (May 2014). "CXCL11-dependent induction of FOXP3-negative regulatory T cells suppresses autoimmune encephalomyelitis". The Journal of Clinical Investigation. 124 (5): 2009–2022. doi:10.1172/JCI71951. PMC 4001543. PMID 24713654. (This paper currently has an expression of concern, see doi:10.1172/JCI97015, PMID 28846074. If this is an intentional citation to a such a paper, please replace {{expression of concern|...}} with {{expression of concern|...|intentional=yes}}.)
Oghumu S, Varikuti S, Terrazas C, Kotov D, Nasser MW, Powell CA, et al. (September 2014). "CXCR3 deficiency enhances tumor progression by promoting macrophage M2 polarization in a murine breast cancer model". Immunology. 143 (1): 109–119. doi:10.1111/imm.12293. PMC 4137960. PMID 24679047.
Mosser DM, Edwards JP (December 2008). "Exploring the full spectrum of macrophage activation". Nature Reviews. Immunology. 8 (12): 958–969. doi:10.1038/nri2448. PMC 2724991. PMID 19029990.
Peng W, Liu C, Xu C, Lou Y, Chen J, Yang Y, et al. (October 2012). "PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines". Cancer Research. 72 (20): 5209–5218. doi:10.1158/0008-5472.CAN-12-1187. PMC 3476734. PMID 22915761.
Ji RR, Chasalow SD, Wang L, Hamid O, Schmidt H, Cogswell J, et al. (July 2012). "An immune-active tumor microenvironment favors clinical response to ipilimumab". Cancer Immunology, Immunotherapy. 61 (7): 1019–1031. doi:10.1007/s00262-011-1172-6. PMC 11028506. PMID 22146893. S2CID 8464711.
Altara R, Gu YM, Struijker-Boudier HA, Thijs L, Staessen JA, Blankesteijn WM (2015). "Left Ventricular Dysfunction and CXCR3 Ligands in Hypertension: From Animal Experiments to a Population-Based Pilot Study". PLOS ONE. 10 (10): e0141394. Bibcode:2015PLoSO..1041394A. doi:10.1371/journal.pone.0141394. PMC 4624781. PMID 26506526.
Altara R, Manca M, Hessel MH, Gu Y, van Vark LC, Akkerhuis KM, et al. (August 2016). "CXCL10 Is a Circulating Inflammatory Marker in Patients with Advanced Heart Failure: a Pilot Study". Journal of Cardiovascular Translational Research. 9 (4): 302–314. doi:10.1007/s12265-016-9703-3. PMID 27271043. S2CID 41188765.
Jansen AF, Schoffelen T, Textoris J, Mege JL, Nabuurs-Franssen M, Raijmakers RP, et al. (August 2017). "CXCL9, a promising biomarker in the diagnosis of chronic Q fever". BMC Infectious Diseases. 17 (1): 556. doi:10.1186/s12879-017-2656-6. PMC 5551022. PMID 28793883.
Bedognetti D, Spivey TL, Zhao Y, Uccellini L, Tomei S, Dudley ME, et al. (October 2013). "CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2". British Journal of Cancer. 109 (9): 2412–2423. doi:10.1038/bjc.2013.557. PMC 3817317. PMID 24129241.
Lasagni L, Francalanci M, Annunziato F, Lazzeri E, Giannini S, Cosmi L, et al. (June 2003). "An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4". The Journal of Experimental Medicine. 197 (11): 1537–1549. doi:10.1084/jem.20021897. PMC 2193908. PMID 12782716.
Weng Y, Siciliano SJ, Waldburger KE, Sirotina-Meisher A, Staruch MJ, Daugherty BL, et al. (July 1998). "Binding and functional properties of recombinant and endogenous CXCR3 chemokine receptors". The Journal of Biological Chemistry. 273 (29): 18288–18291. doi:10.1074/jbc.273.29.18288. PMID 9660793.

ensembl.org

May2017.archive.ensembl.org

GRCh38: Ensembl release 89: ENSG00000138755 – Ensembl, May 2017
GRCm38: Ensembl release 89: ENSMUSG00000029417 – Ensembl, May 2017

harvard.edu

ui.adsabs.harvard.edu

Altara R, Gu YM, Struijker-Boudier HA, Thijs L, Staessen JA, Blankesteijn WM (2015). "Left Ventricular Dysfunction and CXCR3 Ligands in Hypertension: From Animal Experiments to a Population-Based Pilot Study". PLOS ONE. 10 (10): e0141394. Bibcode:2015PLoSO..1041394A. doi:10.1371/journal.pone.0141394. PMC 4624781. PMID 26506526.

maastrichtuniversity.nl

cris.maastrichtuniversity.nl

Altara R, Manca M, Hessel MH, Gu Y, van Vark LC, Akkerhuis KM, et al. (August 2016). "CXCL10 Is a Circulating Inflammatory Marker in Patients with Advanced Heart Failure: a Pilot Study". Journal of Cardiovascular Translational Research. 9 (4): 302–314. doi:10.1007/s12265-016-9703-3. PMID 27271043. S2CID 41188765.

nih.gov

pubmed.ncbi.nlm.nih.gov

Tokunaga R, Zhang W, Naseem M, Puccini A, Berger MD, Soni S, et al. (February 2018). "CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy". Cancer Treatment Reviews. 63: 40–47. doi:10.1016/j.ctrv.2017.11.007. PMC 5801162. PMID 29207310.
Lee HH, Farber JM (1996). "Localization of the gene for the human MIG cytokine on chromosome 4q21 adjacent to INP10 reveals a chemokine "mini-cluster"". Cytogenetics and Cell Genetics. 74 (4): 255–258. doi:10.1159/000134428. PMID 8976378.
O'Donovan N, Galvin M, Morgan JG (1999). "Physical mapping of the CXC chemokine locus on human chromosome 4". Cytogenetics and Cell Genetics. 84 (1–2): 39–42. doi:10.1159/000015209. PMID 10343098. S2CID 8087808.
Tensen CP, Flier J, Van Der Raaij-Helmer EM, Sampat-Sardjoepersad S, Van Der Schors RC, Leurs R, et al. (May 1999). "Human IP-9: A keratinocyte-derived high affinity CXC-chemokine ligand for the IP-10/Mig receptor (CXCR3)". The Journal of Investigative Dermatology. 112 (5): 716–722. doi:10.1046/j.1523-1747.1999.00581.x. PMID 10233762.
Valdés N, Espinoza D, Pareja-Barrueto C, Olate N, Barraza-Rojas F, Benavides-Larenas A, et al. (2024). "Expression and regulation of the CXCL9-11 chemokines and CXCR3 receptor in Atlantic salmon (Salmo salar)". Frontiers in Immunology. 15: 1455457. doi:10.3389/fimmu.2024.1455457. PMC 11410577. PMID 39301034.
Schoenborn JR, Wilson CB (2007). Regulation of interferon-gamma during innate and adaptive immune responses. Advances in Immunology. Vol. 96. Elsevier. pp. 41–101. doi:10.1016/s0065-2776(07)96002-2. ISBN 978-0-12-373709-0. PMID 17981204.
Fernandez-Poma SM, Salas-Benito D, Lozano T, Casares N, Riezu-Boj JI, Mancheño U, et al. (July 2017). "+ T cells Expressing PD-1 Improves the Efficacy of Adoptive T-cell Therapy". Cancer Research. 77 (13): 3672–3684. doi:10.1158/0008-5472.CAN-17-0236. PMID 28522749.
Gorbachev AV, Kobayashi H, Kudo D, Tannenbaum CS, Finke JH, Shu S, et al. (2007-02-15). "CXC Chemokine Ligand 9/Monokine Induced by IFN- Production by Tumor Cells Is Critical for T Cell-Mediated Suppression of Cutaneous Tumors". Journal of Immunology. 178 (4). Baltimore, Md.: 2278–2286. doi:10.4049/jimmunol.178.4.2278. ISSN 0022-1767. PMID 17277133.
Zohar Y, Wildbaum G, Novak R, Salzman AL, Thelen M, Alon R, et al. (May 2014). "CXCL11-dependent induction of FOXP3-negative regulatory T cells suppresses autoimmune encephalomyelitis". The Journal of Clinical Investigation. 124 (5): 2009–2022. doi:10.1172/JCI71951. PMC 4001543. PMID 24713654. (This paper currently has an expression of concern, see doi:10.1172/JCI97015, PMID 28846074. If this is an intentional citation to a such a paper, please replace {{expression of concern|...}} with {{expression of concern|...|intentional=yes}}.)
Oghumu S, Varikuti S, Terrazas C, Kotov D, Nasser MW, Powell CA, et al. (September 2014). "CXCR3 deficiency enhances tumor progression by promoting macrophage M2 polarization in a murine breast cancer model". Immunology. 143 (1): 109–119. doi:10.1111/imm.12293. PMC 4137960. PMID 24679047.
Mosser DM, Edwards JP (December 2008). "Exploring the full spectrum of macrophage activation". Nature Reviews. Immunology. 8 (12): 958–969. doi:10.1038/nri2448. PMC 2724991. PMID 19029990.
Peng W, Liu C, Xu C, Lou Y, Chen J, Yang Y, et al. (October 2012). "PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines". Cancer Research. 72 (20): 5209–5218. doi:10.1158/0008-5472.CAN-12-1187. PMC 3476734. PMID 22915761.
Ji RR, Chasalow SD, Wang L, Hamid O, Schmidt H, Cogswell J, et al. (July 2012). "An immune-active tumor microenvironment favors clinical response to ipilimumab". Cancer Immunology, Immunotherapy. 61 (7): 1019–1031. doi:10.1007/s00262-011-1172-6. PMC 11028506. PMID 22146893. S2CID 8464711.
Altara R, Gu YM, Struijker-Boudier HA, Thijs L, Staessen JA, Blankesteijn WM (2015). "Left Ventricular Dysfunction and CXCR3 Ligands in Hypertension: From Animal Experiments to a Population-Based Pilot Study". PLOS ONE. 10 (10): e0141394. Bibcode:2015PLoSO..1041394A. doi:10.1371/journal.pone.0141394. PMC 4624781. PMID 26506526.
Altara R, Manca M, Hessel MH, Gu Y, van Vark LC, Akkerhuis KM, et al. (August 2016). "CXCL10 Is a Circulating Inflammatory Marker in Patients with Advanced Heart Failure: a Pilot Study". Journal of Cardiovascular Translational Research. 9 (4): 302–314. doi:10.1007/s12265-016-9703-3. PMID 27271043. S2CID 41188765.
Jansen AF, Schoffelen T, Textoris J, Mege JL, Nabuurs-Franssen M, Raijmakers RP, et al. (August 2017). "CXCL9, a promising biomarker in the diagnosis of chronic Q fever". BMC Infectious Diseases. 17 (1): 556. doi:10.1186/s12879-017-2656-6. PMC 5551022. PMID 28793883.
Bedognetti D, Spivey TL, Zhao Y, Uccellini L, Tomei S, Dudley ME, et al. (October 2013). "CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2". British Journal of Cancer. 109 (9): 2412–2423. doi:10.1038/bjc.2013.557. PMC 3817317. PMID 24129241.
Lasagni L, Francalanci M, Annunziato F, Lazzeri E, Giannini S, Cosmi L, et al. (June 2003). "An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4". The Journal of Experimental Medicine. 197 (11): 1537–1549. doi:10.1084/jem.20021897. PMC 2193908. PMID 12782716.
Weng Y, Siciliano SJ, Waldburger KE, Sirotina-Meisher A, Staruch MJ, Daugherty BL, et al. (July 1998). "Binding and functional properties of recombinant and endogenous CXCR3 chemokine receptors". The Journal of Biological Chemistry. 273 (29): 18288–18291. doi:10.1074/jbc.273.29.18288. PMID 9660793.

ncbi.nlm.nih.gov

"Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
"Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
Tokunaga R, Zhang W, Naseem M, Puccini A, Berger MD, Soni S, et al. (February 2018). "CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy". Cancer Treatment Reviews. 63: 40–47. doi:10.1016/j.ctrv.2017.11.007. PMC 5801162. PMID 29207310.
Valdés N, Espinoza D, Pareja-Barrueto C, Olate N, Barraza-Rojas F, Benavides-Larenas A, et al. (2024). "Expression and regulation of the CXCL9-11 chemokines and CXCR3 receptor in Atlantic salmon (Salmo salar)". Frontiers in Immunology. 15: 1455457. doi:10.3389/fimmu.2024.1455457. PMC 11410577. PMID 39301034.
Zohar Y, Wildbaum G, Novak R, Salzman AL, Thelen M, Alon R, et al. (May 2014). "CXCL11-dependent induction of FOXP3-negative regulatory T cells suppresses autoimmune encephalomyelitis". The Journal of Clinical Investigation. 124 (5): 2009–2022. doi:10.1172/JCI71951. PMC 4001543. PMID 24713654. (This paper currently has an expression of concern, see doi:10.1172/JCI97015, PMID 28846074. If this is an intentional citation to a such a paper, please replace {{expression of concern|...}} with {{expression of concern|...|intentional=yes}}.)
Oghumu S, Varikuti S, Terrazas C, Kotov D, Nasser MW, Powell CA, et al. (September 2014). "CXCR3 deficiency enhances tumor progression by promoting macrophage M2 polarization in a murine breast cancer model". Immunology. 143 (1): 109–119. doi:10.1111/imm.12293. PMC 4137960. PMID 24679047.
Mosser DM, Edwards JP (December 2008). "Exploring the full spectrum of macrophage activation". Nature Reviews. Immunology. 8 (12): 958–969. doi:10.1038/nri2448. PMC 2724991. PMID 19029990.
Peng W, Liu C, Xu C, Lou Y, Chen J, Yang Y, et al. (October 2012). "PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines". Cancer Research. 72 (20): 5209–5218. doi:10.1158/0008-5472.CAN-12-1187. PMC 3476734. PMID 22915761.
Ji RR, Chasalow SD, Wang L, Hamid O, Schmidt H, Cogswell J, et al. (July 2012). "An immune-active tumor microenvironment favors clinical response to ipilimumab". Cancer Immunology, Immunotherapy. 61 (7): 1019–1031. doi:10.1007/s00262-011-1172-6. PMC 11028506. PMID 22146893. S2CID 8464711.
Altara R, Gu YM, Struijker-Boudier HA, Thijs L, Staessen JA, Blankesteijn WM (2015). "Left Ventricular Dysfunction and CXCR3 Ligands in Hypertension: From Animal Experiments to a Population-Based Pilot Study". PLOS ONE. 10 (10): e0141394. Bibcode:2015PLoSO..1041394A. doi:10.1371/journal.pone.0141394. PMC 4624781. PMID 26506526.
Jansen AF, Schoffelen T, Textoris J, Mege JL, Nabuurs-Franssen M, Raijmakers RP, et al. (August 2017). "CXCL9, a promising biomarker in the diagnosis of chronic Q fever". BMC Infectious Diseases. 17 (1): 556. doi:10.1186/s12879-017-2656-6. PMC 5551022. PMID 28793883.
Bedognetti D, Spivey TL, Zhao Y, Uccellini L, Tomei S, Dudley ME, et al. (October 2013). "CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2". British Journal of Cancer. 109 (9): 2412–2423. doi:10.1038/bjc.2013.557. PMC 3817317. PMID 24129241.
Lasagni L, Francalanci M, Annunziato F, Lazzeri E, Giannini S, Cosmi L, et al. (June 2003). "An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4". The Journal of Experimental Medicine. 197 (11): 1537–1549. doi:10.1084/jem.20021897. PMC 2193908. PMID 12782716.

semanticscholar.org

api.semanticscholar.org

O'Donovan N, Galvin M, Morgan JG (1999). "Physical mapping of the CXC chemokine locus on human chromosome 4". Cytogenetics and Cell Genetics. 84 (1–2): 39–42. doi:10.1159/000015209. PMID 10343098. S2CID 8087808.
Ji RR, Chasalow SD, Wang L, Hamid O, Schmidt H, Cogswell J, et al. (July 2012). "An immune-active tumor microenvironment favors clinical response to ipilimumab". Cancer Immunology, Immunotherapy. 61 (7): 1019–1031. doi:10.1007/s00262-011-1172-6. PMC 11028506. PMID 22146893. S2CID 8464711.
Altara R, Manca M, Hessel MH, Gu Y, van Vark LC, Akkerhuis KM, et al. (August 2016). "CXCL10 Is a Circulating Inflammatory Marker in Patients with Advanced Heart Failure: a Pilot Study". Journal of Cardiovascular Translational Research. 9 (4): 302–314. doi:10.1007/s12265-016-9703-3. PMID 27271043. S2CID 41188765.

worldcat.org

search.worldcat.org

Gorbachev AV, Kobayashi H, Kudo D, Tannenbaum CS, Finke JH, Shu S, et al. (2007-02-15). "CXC Chemokine Ligand 9/Monokine Induced by IFN- Production by Tumor Cells Is Critical for T Cell-Mediated Suppression of Cutaneous Tumors". Journal of Immunology. 178 (4). Baltimore, Md.: 2278–2286. doi:10.4049/jimmunol.178.4.2278. ISSN 0022-1767. PMID 17277133.

zenodo.org

Lee HH, Farber JM (1996). "Localization of the gene for the human MIG cytokine on chromosome 4q21 adjacent to INP10 reveals a chemokine "mini-cluster"". Cytogenetics and Cell Genetics. 74 (4): 255–258. doi:10.1159/000134428. PMID 8976378.